Effect of hyperparathyroidism on anemia management in patients with hemodialysis dependent end stage renal disease

Main Article Content

Ahmed Fadhil Idan
Mostafa Adnan Abdalrahman


Effect, Patients, Stage, management


Anemia is the most serious and significant complication in patients with chronic kidney disease, especially hemodialysis dependent end stage renal disease. Hyperparathyroidism may hamper the management of anemia by multiple mechanisms. So the aim of this study is to define the effect of elevated parathyroid hormone level on anemia management in hemodialysis patients at (The Iraqi center of hemodialysis, Baghdad teaching hospital, Iraq). A retrospective cohort study was conducted in (The Iraqi center of hemodialysis, Baghdad teaching hospital, Iraq). The duration of the study was through six months from the 1st of February to 31st of July of 2022 on 85 hemodialysis patients (after excluded). The data was collected (mentioned in patients and method) and analyzed by the researchers. Results: There was a significantly higher level of hemoglobin (Hb.) with mean 10.55 gm/dl in patients with parathyroid hormone (PTH) level less than 300 pg/ml (G1) comparing 8.6 gm/dl in patients with (PTH) level more than 300 pg/ml(G2) with
p value >0.001 . Other parameter there was a significant difference in serum Ferritin (S. Ferritin) which was higher in G1 than G2 (p value 0.045), although it was within the target range of H.D. patients in both study groups. Serum phosphate (S. PO4), alkaline phosphates and weekly Eprex dose required to achieve targeting Hb. were significantly higher in G2 (p value 0.007, 0.012 and <0.001 respectively.

Abstract 230 | pdf Downloads 168


1. Babitt JL, Lin HY. Mechanisms of anemia in CKD. Journal of the American Society of Nephrology. 2012 Oct 1;23(10):1631-4.
2. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. Journal of the American Society of Nephrology. 2004 Jan 1;15(1 suppl):S21-4.
3. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia .N Engl J Med1993;328:171–5
4. Washio M, Iseki K, Onayoma K et al. Elevation of serum erythropoietin after subtotal parathyroidectomy in chronic hemodialysis
patients . Nephrol Dial Transplant1992;7:121–4.
5. Bogin E, Massry SG, Levi J, Djaldeti M, Bristol G, Smith J.Effect of parathyroid hormone on osmotic fragility of humanerythrocytes.J Clin
6. Mehta R, Cai X, Hodakowski A, Lee J, Leonard M,Ricardo A, Chen J, Hamm L, Sondheimer J, Dobre M,David V, Yang W, Go A, Kusek JW,
Feldman H, Wolf M,Isakova T, CRIC Study Investigators. Fibroblast growth factor 23 and anemia in the chronic renal insufficiency cohort study . Clin J Am Soc Nephrol2017; 12: 1795–1803
7. Trunzo JA, McHenry CR, Schulak JA et al. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease
patients with hyperparathyroidism.Surgery2008;144:915–8.
8. Komaba H, Fukagawa M. Cinacalcet and clinical outcomes indialysis.Semin Dial2015;28:594–603.
9. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis Engl J
10. Battistella M, Richardson RMA, Bargman JM, Chan CT. Improved parathyroid hormone control by cinacalcet is associated with reduction in
darbepoetin requirement in patients with endstage renal disease .Clin Nephrol2011;76:99–103.30.
11. Mpio I, Boumendjel N, Karaaslan H et al. Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study .Nephrol Ther2011;7:229–36.
12. Koizumi M, Komaba H, Nakanishi S, Fujimori A,Fukagawa M. Cinacalcet treatment and serum FGF23 levels in hemodialysis patients with
secondary hyperparathyroidism .Nephrol Dial Transplant2012;27:784–90.33.
13. Moe SM, Chertow GM, Parfrey PS et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the
evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial.Circulation2015;132:27–39.
14. Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM,Stallone C. Calcitriol increases burstforming unit-erythroid proliferation in chronic
renal failure. A synergistic effect withrHuEpo.Nephron Clin Pract2003;95:c121–7.
15. Miskulin D, Majchrzak K, Tighiouart H et al. Ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency: a randomized clinical trial .J Am Soc Nephrol2015;27:1801–10
16. Steddon S, Chesser A, Ashman N, Cunningham J. Oxford handbook of nephrology and hypertension. Oxford University Press; 2014.
17. Tesfaye B, Haile D, Lake B, Belachew T, Tesfaye T, Abera H. Uncontrolled hypertension and associated factors among adult hypertensive
patients on follow-up at Jimma University Teaching and Specialized Hospital: crosssectional study. Research Reports in Clinical Cardiology. 2017;8:21.
18. Jundiah S, Muliani R, Alawiyah E. Relationship Between Anemia And The Quality Of Life Of Clients Of Chronic Kidney Disease Undergoing
Hemodialysis. InProceeding International Conference 2019 Nov 19 (Vol. 1, No. 1, pp. 856-864).
19. Azeem SM, Haroon A, Alam I, Azeem S, Sultana M, Mansoor K. Frequency of anemia in patients with increased level of parathyroid hormone among patients on maintenance hemodialysis. The Professional Medical Journal. 2020 Jun 10;27(06):1255-8.
20. Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, Salusky I, Kalantar-Zadeh K. Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrology Dialysis Transplantation. 2013 Jun 1;28(6):1516-25.
21. Torun D, Yildiz I, Micozkadioglu H, Nursal GN, Yigit F, Ozelsancak R. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary
hyperparathyroidism. Saudi Journal of Kidney Diseases and Transplantation. 2016 Jan 1;27(1):15.
22. Massimetti C, Bellasi A, Feriozzi S. Effects of secondary hyperparathyroidism treatment on hemoglobin levels and erythropoietin doses in
hemodialysis patients. Journal of Clinical Nephrology. 2021 Oct 15;5(3):088-94.
23. Streja E, Lau WL, Goldstein L, Sim JJ, Molnar MZ, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney international supplements. 2013 Dec 2;3(5):462-8.
24. Frazão JM, Braun J, Messa P, Dehmel B, Mattin C, Wilkie M. Is serum phosphorus control related to parathyroid hormone control in dialysis
patients with secondary hyperparathyroidism?. BMC nephrology. 2012 Dec;13(1):1-1.
25. Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. American Journal of Physiology-Renal Physiology. 1999 Nov 1;277(5):F665-75.
26. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003 May;423(6937):337-42.